Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
PVRIG (Poliovirus Receptor Related Immunoglobulin Domain Containing), also known as CD112R, is a coinhibitory immune checkpoint receptor expressed on T cells and NK cells. It binds to Nectin-2/CD112, which is expressed on antigen-presenting cells and tumor cells, leading to the inhibition of T cell and NK cell activity. PVRIG is being investigated as a potential target for cancer immunotherapy to enhance anti-tumor immunity.
Checkpoint inhibition by blocking PVRIG/Nectin-2 interaction, enhancing T cell and NK cell responses.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Poliovirus Receptor Related Immunoglobulin Domain Containing (PVRIG).